Every finding on record at Amedisys Georgia, LLC

Amedisys Home Health is in compliance with 42 CFR Part 418.113, Emergency Preparedness and Covid-19 for HHA, as a result of an onsite survey conducted on 8/19/22 by Surveyors.

A Recertification survey was conducted at Amedisys Home Health, Tifton, Georgia, on 8/19/22 by Surveyors. It revealed that the agency is in compliance with Chapter 42 CFR Part 418, Rules and Requirements for Home Health and Hospice Agencies. The census was 587. Amedisys Home Health is in compliance with 42 CFR Part 418.113, Emergency Preparedness and Covid-19 for HHA, as a result of an onsite survey conducted on 8/19/22 by Surveyors.

A review of all current medications CFR(s): 484.55(c)(5) A review of all medications the patient is currently using in order to identify any potential adverse effects and drug reactions, including ineffective drug therapy, significant side effects, significant drug interactions, duplicate drug therapy, and noncompliance with drug therapy. This ELEMENT is not met as evidenced by: Based on observations, record reviews, and staff interviews, it was determined that the agency failed to ensure that patients’ medication profile and plan of care were updated to reflect current medications at the time of the comprehensive assessment for three (3) of seventeen (17) sampled patients (P#3, #4 and #5). The findings include: A home visit observation was conducted on 8/17/22 at approximately 10:15 a.m., with Physical Therapist Assistant (PTA) DD, for (P#3). The surveyor compared P#3's current medications at patient’s home to the home health agency's medication profile. Discrepancies were found. Patient #3 was admitted to the home health agency on 8/4/22, diagnosed with chronic lymphocytic leak of B Cell type achieve. According to agency medication profile for P#3, physician’s order dated 8/4/22, revealed Paxil 20 milligram (MG), take one tablet one time daily by mouth for depression/anxiety. The pharmacy label revealed Paxil 40 MG take one tablet by mouth daily. PreserVisionAREDS-2 250 MG-90 MG -1 MG chewable tablet one tablet two times a day. PreserVision is not listed on the agency’s medication profile. Spring Valley Cranberry extract 500 MG for urinary tract infection over the counter (OTC) one daily. Cranberry extract 500 MG is not listed on agency’s medication profile. Equate motion sickness 50 MG OTC one tablet prn for motion sickness. Equate motion sickness in not listed on the agency’s medication profile. On 8/16/22 at 10:30 a.m., an interview was conducted with PTA (DD), with PTA (DD) who confirmed she was not aware of medication discrepancies. A home visit observation was conducted on 8/16/22 at approximately 4:15 p.m., with Physical Therapist (PT) CC, for (P#5). The surveyor compared P#5's current medications at patient’s home to the home health agency's medication profile. Discrepancies were found. Patient #5 was admitted to the home health agency on 7/8/22, diagnosed with unspecified open wound of right upper arm, subsequent encounter. According to agency medication profile for P#5, physician’s order dated 7/15/22, revealed Myrbetriq 25 milligrams (MG) tablet extended release, take two tablets two times daily by mouth for overactive bladder. The pharmacy label revealed Myrbetriq 25 MG take one tablet by mouth daily. Prednisone 10 MG tablet take 0.5 tab by mouth daily for inflammation. The pharmacy label revealed Prednisone 10 MG 1 tablet daily by mouth. Zinc 50 MG tablet over the counter (OTC) take 1 tablet daily. Zinc 50 MG ins not listed on the agency’s’ medication profile. Vitamin D2 1.25 MG (50,000 unit) take one capsule by mouth once weekly for 8 weeks then one capsule every two weeks. On pharmacy label Vitamin D2 1.25 MG was started on 5/13/22. On 8/16/22 at 4:35 p.m., an interview was conducted with PT (CC) with PT (CC) who confirmed he was not aware of medication discrepancies. During the observation on 8/17/22, at 11:30 a.m., with Licensed Practical Nurse (LPN) AA, it revealed that P#4’s home medication did not match the agency’s medication profile and plan of care Patient #4 was admitted on 8/10 /22, diagnosed with diverticulitis of large intestine with perforation and colostomy. P#4 was taking oxycodone 5milligrams (mg) one tablet twice daily oral for pain, dated 7/25/22; and Tizanidine hydrochloride, take one capsule daily as needed for muscle spasm, dated 8/8/22. The above medications were not listed in home health agency medication profile and plan of care. On 8/17/22 at 11:30 a.m., an interview was conducted with (LPN) AA, who confirmed that she was not aware of the discrepancy concerning the above medications.

Infection Prevention CFR(s): 484.70(a) Standard: Infection Prevention. The HHA must follow accepted standards of practice, including the use of standard precautions, to prevent the transmission of infections and communicable diseases. This STANDARD is not met as evidenced by: Based on observation and staff interviews, it was determined that the home health agency failed to use standard precaution to prevent infection by placing P#1’s foley bag on the floor. Also, agency failed to maintain clean bag technique. Affected were two (2) of seventeen (17) sampled patients (P#1 and #4). The Finding Include: 1. On 8/16/22 at 3:30 p.m., surveyor observed Registered Nurse (RN) AA, changed P#1’s foley catheter. (RN) AA placed the foley urine bag on the floor. Patient #1 was admitted on 11/14/18, diagnosed with testicular hypofunction, hypertension and encounter for fitting and adjustment of urinary device. On 8/16/22 at 3:58 p.m., an interview was conducted with (RN) AA, stated that she did know better but was nervous, and would take the blame for placing foley urine bag on the floor. 2. On 8/17/22 at 11:30 a.m., surveyor observed Licensed Practical Nurse (LPN) BB, contaminate clean bag technique by putting dirty, used blood pressure cuff in a clean side bag with clean gauzes and gloves. On 8/17/22 at 11:45a.m., an interview was conducted with (LPN) BB, stated that she was nervous, and that caused her to place dirty, used blood pressure cuff inside the clean side.